Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
We have recently shown that VEGF functions as a survival factor for newly formed vessels during developmental neovascularization, but is not required for maintenance of mature vessels. Reasoning that expanding tumors contain a significant fraction of newly formed and remodeling vessels, we examined whether abrupt withdrawal of VEGF will result in regression of preformed tumor vessels. Using a tetracycline-regulated VEGF expression system in xenografted C6 glioma cells, we showed that shutting off VEGF production leads to detachment of endothelial cells from the walls of preformed vessels and their subsequent death by apoptosis. Vascular collapse then leads to hemorrhages and extensive tumor necrosis. These results suggest that enforced withdrawal of vascular survival factors can be applied to target preformed tumor vasculature in established tumors. The system was also used to examine phenotypes resulting from over-expression of VEGF. When expression of the transfected VEGF cDNA was continuously “on,” tumors became hyper-vascularized with abnormally large vessels, presumably arising from excessive fusions. Tumors were significantly less necrotic, suggesting that necrosis in these tumors is the result of insufficient angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., & Keshet, E. (1995) · Nature Medicine · doi:10.1038/nm1095-1024 · Cited by 1,604
Self-citationThe extracellular matrix as a cell survival factor.
Meredith, J. E., Fazeli, B., & Schwartz, M. A. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.9.953 · Cited by 1,526
Programmed Cell Death and the Control of Cell Survival: Lessons from the Nervous System
Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., & Jacobson, M. D. (1993) · Science · doi:10.1126/science.8235590 · Cited by 1,460
Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Cited by
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
“Conversely, the 'improper' or decreased vessel association with pericytes in tumours might partially explain the abnormal vessel diameters and sensitivity to VEGFA inhibitio”
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
“Recent studies have demonstrated that VEGF is a survival factor for newly formed blood vessels such that VEGF withdrawal results in capillary regression (Benjamin and Keshet 1997).”
BackgroundGerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,265
Self-citationBenjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Self-citationKatso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Gerber, H.-P., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 981
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
The splice variants of vascular endothelial growth factor (VEGF) and their receptors
Robinson, C. J., & Stringer, S. E. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.5.853 · Cited by 944
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
VEGF is required for growth and survival in neonatal mice
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 915
Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke
Yang, C., Hawkins, K. E., Doré, S., & Candelario-Jalil, E. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00136.2018 · Cited by 871
“It is known that VEGF functions as a potent proangiogenic factor under physiological and pathological conditions, but it is not required for the maintenance of mature vessels (15).”
BackgroundMolecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
The biology of vascular endothelial growth factors
TAMMELA, T., ENHOLM, B., ALITALO, K., & PAAVONEN, K. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.002 · Cited by 838
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
“is sufficient to produce blood vessel tumors that have hemangiAdditional studies will be required to determine if downregu- oblastoma-like features (Benjamin and Keshet, 1997; Haase et lation of HIF is also sufficient for tumor suppression by pVHL. al., 2001).”
BackgroundInai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
Nör, J. E., Christensen, J., Mooney, D. J., & Polverini, P. J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65284-4 · Cited by 641
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
BHATT, A. J., PRYHUBER, G. S., HUYCK, H., WATKINS, R. H., METLAY, L. A., & MANISCALCO, W. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.10.2101140 · Cited by 602
JunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress
Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., Pouysségur, J., Yaniv, M., & Mechta-Grigoriou, F. (2004) · Cell · doi:10.1016/j.cell.2004.08.025 · Cited by 588
Relationship between RPE and Choriocapillaris in Age-Related Macular Degeneration
McLeod, D. S., Grebe, R., Bhutto, I., Merges, C., Baba, T., & Lutty, G. A. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3639 · Cited by 567
Korff, T., & Augustin, H. G. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.5.1341 · Cited by 559
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
VEGF Receptor Signaling in Tumor Angiogenesis
McMahon, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-3 · Cited by 519
VEGFs, receptors and angiogenesis
Veikkola, T., & Alitalo, K. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0091 · Cited by 508
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
VEGF-A and the Induction of Pathological Angiogenesis
Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.134925 · Cited by 474
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8795 · Cited by 443
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
Self-citationAspects of Human Fetoplacental Vasculogenesis and Angiogenesis. II. Changes During Normal Pregnancy
Kaufmann, P., Mayhew, T. M., & Charnock-Jones, D. S. (2004) · Placenta · doi:10.1016/j.placenta.2003.10.009 · Cited by 437
Miquerol, L., Langille, B. L., & Nagy, A. (2000) · Development · doi:10.1242/dev.127.18.3941 · Cited by 429
Endothelial Cell Apoptosis in Angiogenesis and Vessel Regression
Dimmeler, S., & Zeiher, A. M. (2000) · Circulation Research · doi:10.1161/01.res.87.6.434 · Cited by 425
Kotch, L. E., Iyer, N. V., Laughner, E., & Semenza, G. L. (1999) · Developmental Biology · doi:10.1006/dbio.1999.9253 · Cited by 418
Dor, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/21.8.1939 · Cited by 390
Hoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382
Vascular endothelial growth factor family of ligands and receptors: Review
Otrock, Z. K., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2006.12.003 · Cited by 376
Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., & Keshet, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10820 · Cited by 374
Self-citationBaffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu-Lowe, D., & McDonald, D. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00616.2005 · Cited by 374
KORFF, T., KIMMINA, S., MARTINY‐BARON, G., & AUGUSTIN, H. G. (2001) · The FASEB Journal · doi:10.1096/fj.00-0139com · Cited by 369
Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion
Grobben, B., De Deyn, P., & Slegers, H. (2002) · Cell and Tissue Research · doi:10.1007/s00441-002-0651-7 · Cited by 365
Ahmed, A., Dunk, C., Ahmad, S., & Khaliq, A. (2000) · Placenta · doi:10.1053/plac.1999.0524 · Cited by 349
Masood, R., Cai, J., Zheng, T., Smith, D. L., Hinton, D. R., & Gill, P. S. (2001) · Blood · doi:10.1182/blood.v98.6.1904 · Cited by 343
Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells
O'Connor, D. S., Schechner, J. S., Adida, C., Mesri, M., Rothermel, A. L., Li, F., Nath, A. K., Pober, J. S., & Altieri, D. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64742-6 · Cited by 341
Kaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., & Kerbel, R. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1589 · Cited by 333
Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer
Gasparini, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-37 · Cited by 322
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
Gagnon, M. L., Bielenberg, D. R., Gechtman, Z., Miao, H.-Q., Takashima, S., Soker, S., & Klagsbrun, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040337597 · Cited by 313
Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis)
Scholz, D., Ito, W., Fleming, I., Deindl, E., Sauer, A., Wiesnet, M., Busse, R., Schaper, J., & Schaper, W. (2000) · Virchows Archiv · doi:10.1007/s004280050039 · Cited by 309
DVORAK, H. F. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01361.x · Cited by 296
Sieczkiewicz, G. J., Hussain, M., & Kohn, E. C. (2002) · Ovarian Cancer · doi:10.1007/978-1-4757-3587-1_17 · Cited by 295
Zagzag, D., Amirnovin, R., Greco, M. A., Yee, H., Holash, J., Wiegand, S. J., Zabski, S., Yancopoulos, G. D., & Grumet, M. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780088 · Cited by 292
Regulation of Endothelial Cell Survival and Apoptosis During Angiogenesis
Chavakis, E., & Dimmeler, S. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000017728.55907.a9 · Cited by 285
Causes and Effects of Heterogeneous Perfusion in Tumors
Gillies, R. J., Schomack, P. A., Secomb, T. W., & Raghunand, N. (1999) · Neoplasia · doi:10.1038/sj.neo.7900037 · Cited by 283
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Fibronectins in vascular morphogenesis
Astrof, S., & Hynes, R. O. (2009) · Angiogenesis · doi:10.1007/s10456-009-9136-6 · Cited by 271
Vascular endothelial growth factor and endometriotic angiogenesis
McLaren, J. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.1.45 · Cited by 269
Okada, F., Rak, J. W., Croix, B. S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3609 · Cited by 267
Mahooti, N. I., & Madri, J. A. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.24.3621 · Cited by 266
Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
Saaristo, A., Karpanen, T., & Alitalo, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203969 · Cited by 264
Molecular basis of endothelial cell morphogenesis in three‐dimensional extracellular matrices
Davis, G. E., Bayless, K. J., & Mavila, A. (2002) · The Anatomical Record · doi:10.1002/ar.10159 · Cited by 253
Dor, Y., Camenisch, T. D., Itin, A., Fishman, G. I., McDonald, J. A., Carmeliet, P., & Keshet, E. (2001) · Development · doi:10.1242/dev.128.9.1531 · Cited by 240
Self-citationThe Id proteins and angiogenesis
Benezra, R., Rafii, S., & Lyden, D. (2001) · Oncogene · doi:10.1038/sj.onc.1205160 · Cited by 222
“However, it is known that conditional removal of VEGF results in rapid ablation of newly formed immature tumor endothelial cells (Benjamin et al., 1999; Benjamin and Keshet, 1997).”
BackgroundThe Role of Neuropilin in Vascular and Tumor Biology
Klagsbrun, M., Takashima, S., & Mamluk, R. (2002) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0119-0_3 · Cited by 220
Bi, W., Drake, C. J., & Schwarz, J. J. (1999) · Developmental Biology · doi:10.1006/dbio.1999.9307 · Cited by 181
Zeng, H., Qin, L., Zhao, D., Tan, X., Manseau, E. J., Van Hoang, M., Senger, D. R., Brown, L. F., Nagy, J. A., & Dvorak, H. F. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051523 · Cited by 164
“HUVECs undergo apoptosis when cultured in the absence of serum and VEGF-A165 is known to protect endothelial cells from apoptosis (13).”
BackgroundHan, J.-Y., Oh, S. H., Morgillo, F., Myers, J. N., Kim, E., Hong, W. K., & Lee, H.-Y. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji251 · Cited by 99
Metadata
- Authors
- Benjamin, L. E., & Keshet, E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-08-05
- Volume
- 94
- Issue
- 16
- Pages
- 8761-8766
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2004239325
- Cited by
- 506
- References
- 37
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.